0  -1%
Previous Close 20.80
Open 20.95
Price To book 3.40
Market Cap 546.17M
Shares 26,513,000
Volume 248,646
Short Ratio 6.59
Av. Daily Volume 274,623

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 2H 2017.
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017
  2. Blog Coverage Jazz Pharmaceuticals Inks License Agreement with Nippon Shinyaku
  3. REGENXBIO Enhances and Expands Scientific Leadership
  4. Regenxbio Leads Biotech Movers Ahead of Market's Open
  5. Regenxbio Sinks After Announcing Secondary Offering
  6. REGENXBIO Announces Pricing of Public Offering of Common Stock
  7. REGENXBIO Announces Proposed Public Offering of Common Stock
  8. 6 Stocks Trending Up With Big Volume
  9. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  10. Regenxbio reports 4Q loss
  11. REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
  12. REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia
  13. REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference
  14. REGENXBIO Honors Rare Disease Day® 2017
  15. REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
  16. Rockville gene therapy company to begin trials for treatment for leading cause of blindness
  17. REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration
  18. REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
  19. REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
  20. D.C.-area biotech stocks fall on Trump's tough talk on industry